Last checked at 16 Jul 2018 10:58
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: | Consort Medical PLC |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | N/A |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree | Consort Medical PLC (offeror) |
(d) Is the discloser the offeror or the offeree? | OFFEROR |
(e) Date position held: The latest practicable date prior to the disclosure | 13 July 2018 |
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | NO
|
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates
Class of relevant security:
| Ordinary shares of 10 pence each in Consort Medical plc | |||
| Interests | Short positions | ||
Number | % | Number | % | |
(1) Relevant securities owned and/or controlled: | Nil | Nil | Nil | Nil |
(2) Cash-settled derivatives:
| Nil | Nil | Nil | Nil |
(3) Stock-settled derivatives (including options) and agreements to purchase/sell: | Nil | Nil | Nil | Nil |
TOTAL: | Nil | Nil | Nil | Nil |
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: | N/A |
Details, including nature of the rights concerned and relevant percentages: | N/A |
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure: | ||
a) Interests of the directors of Consort Medical plc in the ordinary shares of 10 pence each in Consort Medical plc
| ||
Director | No. of ordinary shares held | % of total issued share capital of Consort Medical plc |
Jonathan Glenn (1) | 165,354 | 0.335 |
Paul Hayes(2) | 8,157 | 0.017 |
Dr Peter Fellner | 6,500 | 0.013 |
Dr William Jenkins | 1,625 | 0.003 |
Andrew Hosty | 1,579 | 0.003 |
Ian Nicholson | 1,000 | 0.002 |
Steve Crummett(3) | 1,000 | 0.002 |
Charlotta Finman(4) | 948 | 0.002 |
(1) 8,429 shares held under the share incentive plan scheme and 118,101 shares held by Jonathan Glenn's wife, Janis Glenn.
(2) 4,000 shares held in an ISA, 4,000 shares held in a self-invested personal pension and 157 shares held in the share incentive plan scheme.
(3) held in a nominee account for the benefit of Mrs Skerry Crummett
(4) held in a nominee account with Hargreaves Lansdowne
b) Interests of the directors of Consort Medical plc in awards of ordinary shares of 10 pence each under the Performance Share Plan (PSP), Deferred Bonus Plan (DBP) and Save As You Earn (SAYE) plan of Consort Medical plc
| ||||
Director | Scheme | No. of Ordinary Shares | Vesting Dates | % of total issued share capital of Consort Medical plc |
Jonathan Glenn | PSP | 182,580 | June 2018, June 2019, June 2020 and June 2021 | 0.370 |
Jonathan Glenn | DBP | 49,957 | June 2019, June 2020 and June 2021 | 0.101 |
Jonathan Glenn | SAYE | 1,853 | September 2018 and September 2020 | 0.004 |
Paul Hayes | PSP | 55,942 | June 2020 and June 2021 | 0.113 |
Paul Hayes
| DBP | 8,629 | June 2021 | 0.018 |
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" |
None.
|
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" |
None.
|
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) | NO |
Supplemental Form 8 (SBL) | NO |
| Date of disclosure: | 16 July 2018 |
| Contact name: | Michelle Palmer |
| Telephone number: | +44 (0) 1442 867 920 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.